J.R. Landry became one of only a handful in the nation, and the first in Rhode Island, to get what doctors believe will be ...

A gene transfer approach to treating the bleeding disorder hemophilia B remains safe and effective long-term, as scientists ...

Hemophilia A Market Trends The report provides a detailed analysis of the current hemophilia A marketed drugs and late-stage pipeline drugs ...

Consider alternative treatment for hemophilia in patients with a history of symptomatic gallbladder disease. Serious thrombotic events have been reported in Qfitlia-treated patients. Thrombotic ...

It was found that those with severe hemophilia B have less than 1% of normal factor IX activity, often experiencing spontaneous bleeding that can cause joint damage or life-threatening events.

According to a new study in Haemophilia, up to 60% of patients with severe HA have no known family history, making early ...

Researchers from the Centenary Institute have uncovered a reason why some people with hemophilia A develop resistance to their critical treatment, paving the way for the development of more ...

Subsequent studies by other investigators confirmed those early results, ultimately leading to the FDA approval of ...

In a 13-year follow-up by St. Jude Children’s Research Hospital and University College London published in The New England ...

Developed by ICMR, kit can detect Hemophilia & Von Willebrand Disease within minutes. In India alone, it could identify over ...

The Hemophilia B treatment landscape is entering a new era, marked by disruptive innovation, curative potential, and renewed global attention. Once viewed as a lifelong burden requiring constant ...